AXA Investment Managers’s Ultragenyx Pharmaceutical RARE Stock Holding History

AXA Investment Managers’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$12.5M	Buy	+417,198	New	+$12.5M	0.03%	364

Other funds holding RARE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

AXA Investment Managers's RARE Position: Q3 2025 in Review

AXA Investment Managers opened a new position in Ultragenyx Pharmaceutical (RARE) in Q3 2025: 417,198 shares worth $12.5M. The stake represents 0.03% of the portfolio and ranks #364 among its holdings.

302 funds tracked by Wall St. Rank hold RARE as of Q3 2025.

AXA Investment Managers held 417,198 shares of Ultragenyx Pharmaceutical worth $12.5M as of Q3 2025.
Ultragenyx Pharmaceutical was a new AXA Investment Managers position in Q3 2025.
Ultragenyx Pharmaceutical made up 0.03% of AXA Investment Managers's portfolio in Q3 2025, its #364 holding.
302 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2025.

Based on AXA Investment Managers's 13F filing for Q3 2025, filed 14 Nov 2025.